A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]

Singh RP, Srivastava SK, Ehlers JP, et al. Clin Ophthalmol. 2015;9:1759–1766.On page 1763, Figure 4 has been amended. Read the original article

Guardado en:

Detalles Bibliográficos
Autores principales:	Singh RP, Srivastava SK, Ehlers JP, Silva FQ, Bedi R, Schachat AP, Kaiser PK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/239904354ae741d0b8a664e266ab236e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:239904354ae741d0b8a664e266ab236e
record_format	dspace
spelling	oai:doaj.org-article:239904354ae741d0b8a664e266ab236e2021-12-02T07:23:35ZA single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]1177-5483https://doaj.org/article/239904354ae741d0b8a664e266ab236e2017-02-01T00:00:00Zhttps://www.dovepress.com/httpswwwdovepresscomcorrigendum-a-single-arm-investigator--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Singh RP, Srivastava SK, Ehlers JP, et al. Clin Ophthalmol. 2015;9:1759–1766.On page 1763, Figure 4 has been amended. Read the original articleSingh RPSrivastava SKEhlers JPSilva FQBedi RSchachat APKaiser PKDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 303-304 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Singh RP Srivastava SK Ehlers JP Silva FQ Bedi R Schachat AP Kaiser PK A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
description	Singh RP, Srivastava SK, Ehlers JP, et al. Clin Ophthalmol. 2015;9:1759–1766.On page 1763, Figure 4 has been amended. Read the original article
format	article
author	Singh RP Srivastava SK Ehlers JP Silva FQ Bedi R Schachat AP Kaiser PK
author_facet	Singh RP Srivastava SK Ehlers JP Silva FQ Bedi R Schachat AP Kaiser PK
author_sort	Singh RP
title	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_short	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_full	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_fullStr	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_full_unstemmed	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
title_sort	single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (assess study): 12-month analysis [corrigendum]
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/239904354ae741d0b8a664e266ab236e
work_keys_str_mv	AT singhrp asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT srivastavask asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT ehlersjp asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT silvafq asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT bedir asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT schachatap asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT kaiserpk asinglearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT singhrp singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT srivastavask singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT ehlersjp singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT silvafq singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT bedir singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT schachatap singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum AT kaiserpk singlearminvestigatorinitiatedstudyoftheefficacysafetyandtolerabilityofintravitrealafliberceptinjectioninsubjectswithexudativeagerelatedmaculardegenerationpreviouslytreatedwithranibizumaborbevacizumabassessstudy12monthanalysiscorrigendum
_version_	1718399445917237248

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]

Ejemplares similares